Blood cancer Clinical Trials

Recruiting blood cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.

Clinical trials study new ways to prevent, detect, or treat blood cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting blood cancer studies with sites across the US; use the location tools to find ones near you.

What to expect

Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.

Recruiting blood cancer trials

Within

MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma

for Multiple Myeloma

1 site in Burlington

Sponsor: University of Vermont Medical Center

Sex: All·Age: 18+

Code: NCT07783607

Universal 4SCAR7U Targeting CD7-positive Malignancies

for T-cell Acute Lymphoblastic Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 6 Months - 75

Code: NCT05995028·Phase 1

Universal CAR-T Cells Targeting AML

for Acute Myeloid Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 6 Months - 75

Code: NCT05995041·Phase 1

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

for Multiple Myeloma

1 site in Seattle

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18 - 70

Code: NCT04579523·Phase 1

A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)

for Myelodysplastic Syndromes

Sponsor: Kyntra Bio

Sex: All·Age: 18+

Code: NCT07722988·Phase 3

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

27 sites incl. Bloomington

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 60+

Code: NCT07437950·Phase 2

Apply to this trial

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

for Recurrent Multiple Myeloma

1 site in Philadelphia

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07463807·Phase 1, Phase 2

Apply to this trial

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia With Complex Karyotype

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07582172·Phase 2

Apply to this trial

BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.

for Waldenstrom Macroglobulinaemia

Sponsor: Anne Louise Tølbøll Sørensen

Sex: All·Age: 18+

Code: NCT07474961·Phase 4

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

for Hematologic Malignancies

Sponsor: Asmaa Hassan mohamed Abdel Mawjoud

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT04546945

Apply to this trial

Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease

for Chronic Graft Versus Host Disease

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07733141

The High Fiber Program to Increase Fiber Intake Among Patients Undergoing Allogeneic Hematopoietic Cell Transplant

for Hematopoietic and Lymphatic System Neoplasm

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07664670

Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

for Randomized

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07783594·Phase 2

GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors

for Acute Myeloid Leukemia

Sponsor: Vitruviae

Sex: All·Age: 6 Months+

Code: NCT07749976·Phase 1, Phase 2

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

for Diffuse Large B-Cell Lymphoma (DLBCL)

1 site in Houston

Sponsor: The Methodist Hospital Research Institute

Sex: All·Age: 16 - 75

Code: NCT07729397·Phase 1

A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma

for Follicular Lymphoma

Sponsor: Australasian Leukaemia and Lymphoma Group

Sex: All·Age: 18+

Code: NCT07736950·Phase 3

Dyadic Physical Activity Intervention for Children Undergoing Cancer Treatment

for Leukemia

Sponsor: The Hong Kong Polytechnic University

Sex: All·Age: 9 - 18

Code: NCT07737418

Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

for Acute Myeloid Leukemia (AML)

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07780565·Phase 1

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

for Acute Myeloid Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 2 - 75

Code: NCT03222674·Phase 1, Phase 2

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

for Multiple Myeloma

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 18 - 80

Code: NCT03271632·Phase 1, Phase 2

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

for T-cell Acute Lymphoblastic Leukemia

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 6 Months - 75

Code: NCT04033302·Phase 1, Phase 2

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

for Multiple Myeloma

Sponsor: Shenzhen Geno-Immune Medical Institute

Sex: All·Age: 18 - 80

Code: NCT06429150·Phase 1, Phase 2

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

for Refractory Acute Myeloid Leukemia (AML)

1 site in Aurora

Sponsor: University of Colorado, Denver

Sex: All·Age: 18+

Code: NCT07347418·Phase 1

Apply to this trial

Menin-Inhibitor Targeted Maintenance in AML

for Relapsed Adult AML

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: 18+

Code: NCT07563010·Phase 2

A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

for Chronic Lymphocytic Leukemia

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT07674810·Phase 2

Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

for Chronic Lymphocytic Leukemia

Sponsor: The Lymphoma Academic Research Organisation

Sex: All·Age: 18 - 79

Code: NCT07738887·Phase 2

Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

for Chronic Lymphocytic Leukemia

Sponsor: The Lymphoma Academic Research Organisation

Sex: All·Age: 80+

Code: NCT07739459·Phase 2

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

for Non-Hodgkin Lymphoma Refractory/ Relapsed

Sponsor: Luminary Therapeutics

Sex: All·Age: 18+

Code: NCT07771361·Phase 2

A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma

for Lymphoma

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sex: All·Age: 18+

Code: NCT07791615·Phase 2

Adoption of Audio Recording in the Outpatient Supportive Care Center

for Advanced Malignant Solid Neoplasm

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18+

Code: NCT04871477

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

for Large B-cell Lymphoma

1 site in Houston

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 18 - 75

Code: NCT07164469·Phase 2

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

2 sites incl. Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07582159·Phase 2

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07583810·Phase 2

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

for Recurrent Acute Myeloid Leukemia

1 site in Duarte

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+

Code: NCT07583303·Phase 1

Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients

for Diffuse Large B-Cell Lymphoma

1 site in Los Angeles

Sponsor: Jonsson Comprehensive Cancer Center

Sex: All·Age: 70+

Code: NCT07714421·Phase 1

Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol

for Hematopoietic Neoplasm

Sponsor: City of Hope Medical Center

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07691008

Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies

for Hematologic Malignancy

Sponsor: Ossium Health, Inc.

Sex: All·Age: 12 - 75

Code: NCT07710781

Revumenib in Patients With Myelofibrosis

for Myelofibrosis

1 site in New York

Sponsor: John Mascarenhas

Sex: All·Age: 18+

Code: NCT07734077·Phase 1, Phase 2

Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia

for Acute Myeloid Leukemia

1 site in Rochester

Sponsor: University of Rochester

Sex: All·Age: 60+

Code: NCT07735208·Phase 2

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

for Acute Myeloid Leukemia

1 site in Ann Arbor

Sponsor: University of Michigan Rogel Cancer Center

Sex: All·Age: 21+

Code: NCT07737769·Phase 1

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

for Myelofibrosis

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd

Sex: All·Age: 18+

Code: NCT07750574·Phase 2

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

for Myelofibrosis

Sponsor: United Lincolnshire Hospitals NHS Trust

Sex: All·Age: 18 - 99

Code: NCT07424950·Phase 2

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

for Diffuse Large B Cell Lymphoma

1 site in Providence

Sponsor: Brown University

Sex: All·Age: 18+

Code: NCT07502872·Phase 2

INfections in Patients Treated With CAR-T

for Relapsed Multiple Myeloma

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Sex: All·Age: 18+

Code: NCT07713511

Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study

for Hematopoietic and Lymphatic System Neoplasm

1 site in Seattle

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18+

Code: NCT07737314

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

for Relapse Multiple Myeloma

1 site in Milwaukee

Sponsor: Medical College of Wisconsin

Sex: All·Age: 18 - 80

Code: NCT07221032·Phase 1

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

for Acute Lymphoid Leukemia

1 site in Tucson

Sponsor: University of Arizona

Sex: All·Age: Up to 65

Code: NCT07254793·Phase 1

Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas

for Large B-cell Lymphoma

1 site in Cleveland

Sponsor: Allison Winter

Sex: All·Age: 18+

Code: NCT07608731·Phase 1

Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging

for Monoclonal Gammopathy

Sponsor: University of Zurich

Sex: All·Age: 18+

Code: NCT07624760

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients

for Myeloproliferative Neoplasm

Sponsor: Weizmann Institute of Science

Sex: All·Age: 18+

Code: NCT07648433

Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Transfusions

for Myelodysplastic Syndromes

Sponsor: Halia Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07738510·Phase 2

Allogeneic iNKT Cell Therapy (agenT-797) After SCT

for Allogenic Stem Cell Transplantation

1 site in Madison

Sponsor: University of Wisconsin, Madison

Sex: All·Age: 18+

Code: NCT07758218·Phase 1

A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

for Relapsed Acute Myeloid Leukemia

Sponsor: BeOne Medicines

Sex: All·Age: 6 Months - 17

Code: NCT07770698·Phase 1, Phase 2

CHIP in Health and Disease

for Clonal Hematopoiesis

Sponsor: VASCage GmbH

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07780552

A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

for Multiple Myeloma

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07609706·Phase 1

A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

for Multiple Myeloma

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07742527·Phase 1

GLORY: Glofit-GemOx With Liso-Cel For Lymphoma

for Lymphoma

2 sites in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT07711483·Phase 2

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

for Burkitt Lymphoma

8 sites incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07069699·Phase 1, Phase 2

Apply to this trial

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

for Acute Myeloid Leukemia

Sponsor: Institut Paoli-Calmettes

Sex: All·Age: 18 - 75

Code: NCT07598110·Phase 2

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

for Relapsed Pediatric ALL

1 site in Memphis

Sponsor: St. Jude Children's Research Hospital

Sex: All·Age: Up to 21

Code: NCT07257419·Phase 1

Apply to this trial

New trials in Duarte, CA?

Pick a condition and we'll email you once a week when a new study starts recruiting in Duarte, CA. Unsubscribe anytime.

Blood cancer clinical trials — common questions

Are blood cancer clinical trials free to join?

Yes. Participating in a blood cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.

Who can join a blood cancer clinical trial?

Each blood cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.

How do I find a blood cancer trial near me?

Use the location controls above. We'll show recruiting blood cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.

How many blood cancer trials are recruiting right now?

We're currently tracking roughly 1642 recruiting blood cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.

Looking for a specific location? Browse trials by city and state.

Blood cancer trials by city

Duarte, CA Boston, MA Birmingham, AL Seattle, WA Miami, FL Los Angeles, CA Columbus, OH Chicago, IL Portland, OR Aurora, CO Milwaukee, WI Tampa, FL

Conditions in this area

Multiple myeloma Acute myeloid leukemia (AML)Chronic lymphocytic leukemia (CLL)Chronic myelomonocytic leukemia Acute lymphoblastic leukemia Leukemia (other)Myelodysplastic syndromes (MDS)Myelofibrosis Myeloproliferative neoplasm Hodgkin lymphoma Non-Hodgkin lymphoma Diffuse large B-cell lymphoma (DLBCL)Follicular lymphoma Mantle cell lymphoma Marginal zone lymphoma Small lymphocytic lymphoma